350
+1.45%
Close of 9 Nov 2026, in JPY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Stella Pharma
Its shares trade on Tokyo Stock Exchange under the ticker 4888.T. It has been listed since 22 April 2021. In the fiscal year to 31 March 2026, it reported revenue of ¥323.4m and a net loss of ¥780.9m. At that date it held total assets of ¥4.49bn and shareholders' equity of ¥2.43bn.
Stella Pharma Corp. engages in the development, manufacture, and sale of pharmaceuticals. The company is headquartered in Osaka, Osaka-Fu. The company went IPO on 2021-04-22. The company is engaged in the research and development of boron drugs for boron neutron capture therapy (BNCT). BNCT is a radiation therapy that selectively destroys cancer cells by utilizing the fission reaction of B-10, which is a stable isotope of boron, and thermal neutrons with low energy. Nucleus of B-10, which is a stable isotope of boron, absorbs low-energy low-speed neutrons and immediately splits into a helium nucleus (4He nucleus (α particle)) and a lithium nuclei (7Li nuclei). When a substance containing B-10 selectively accumulates in cancer cells and is irradiated with thermal neutrons, cancer cells are selectively destroyed. Product includes steboronin (SPM-011). A phase II clinical trial is conducted for brain tumor, head and neck cancer and recurrent malignant glioma. Phase I clinical trial is started for malignant melanoma, a type of skin cancer, and angiosarcoma.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 22 Apr 2021
- Employees
- 46
- Website
- stella-pharma.co.jp ↗
Leadership
Pay as last reported
- Mr. Koki UeharaPresident, Chief Operating Officer, Representative Director, since 2012
- Mr. Hirotaka OgawaExecutive Officer, Director of General Affairs
- Mr. Kenji OzakiExecutive Officer, Chief Director of Reliability Guarantee
- Mr. Toshimitsu HayashiDirector of Pharmaceutical Affairs, Director of Clinical Development, Director, since 2020
- Mr. Takahiro KidoDirector of Business Planning, Director, since 2018
- Mr. Kazumitsu YabuDirector, since 2015
- Mr. Yoshiyuki FukuchiIndependent Director
- Mr. Masaya OnishiIndependent Director
- Mr. Kohei TsujiiIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Stella Pharma Corp develops specialized boron drugs for targeted cancer therapy in Japan.
- The company employs 46 full-time staff dedicated to pharmaceutical research and development.
- Product steboronin (SPM-011) is a key asset in the company's oncology pipeline.
Weaknesses
- The small workforce of 46 employees limits operational capacity and scalability.
- The company is headquartered in Osaka, which may restrict access to broader markets.
- Listing on 22 April 2021 indicates a relatively young public market presence.
Opportunities
- Phase II clinical trials for brain tumors offer significant growth potential.
- Expanding trials for head and neck cancer could broaden the patient base.
- Phase I trials for malignant melanoma present new therapeutic avenues.
Threats
- Regulatory hurdles in Japan could delay approval for boron neutron capture therapy.
- Competition in the pharmaceuticals sector may reduce market share for steboronin.
- Clinical trial failures for recurrent malignant glioma could impact investor confidence.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.